Theratechnologies
Privately held: no public share price
Assets
(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Donidalorsen(Dawnzera) | Approved | Prekallikrein (PKK) mRNARNA / oligonucleotide | Hereditary Angioedema |
Ibalizumab(Trogarzo) | Approved | CD4 receptorMonoclonal antibody | HIV |
Olezarsen(Tryngolza) | Approved | APOC3RNA / oligonucleotide | Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia Hypertriglyceridemia |
Tesamorelin(Egrifta WR) | Approved | Growth hormone-releasing hormone (GHRH) receptorPeptide | HIV |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12 · NCT05392114 · CT.gov ↗
What to watch
2027 (2)
2028 (1)
February 2028 (1)
Est. primary completion 2028-02 · NCT05130450 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Est. primary completion 2029-06 · NCT07298447 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Est. primary completion 2030-08 · NCT07727538 · CT.gov ↗
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent